News Headlines

Inside the New Drug Pipeline

Big Money Bets on a New Generation of Hair-Loss Treatments

Investors are pouring capital into hair-loss research, demonstrating confidence that science may deliver meaningful improvements beyond treatments like minoxidil and finasteride. In the past three months alone, two biotechs have raised at least $270 million. Veradermics, which is developing the first extended-release oral minoxidil, closed an oversubscribed $150 million Series C financing and Pelage Pharmaceuticals secured $120 million in Series B to push its regenerative topical program, PP405.